HEADWAY

Axovant Sciences Ltd (NASDAQ: AXON) suffered a setback in its phase 3 trial called MINDSET in which its exploratory drug called intepirdine failed to improve the quality of life in people suffering from Alzheimer's. The drug isn't intended to be a cure for the disease but the company expected the...